The results of this large phase III clinical trial showed that the addition of chemotherapy did not significantly improve OS compared with endocrine therapy alone in patients with ER‐positive, HER2‐negative, high‐GGI breast cancer. Here, ERBB2 is linked to breast carcinoma.